Population pharmacokinetics II: Estimation methods

被引:68
作者
Ette, EI
Williams, PJ
机构
[1] Vertex Pharmaceut Inc, Clin Pharmacol, Cambridge, MA 02139 USA
[2] Trials Design LLC, Stockton, CA USA
[3] Univ Pacific, Sch Pharm, Dept Pharm Practice, Stockton, CA 95211 USA
关键词
estimation; pharmacokinetics; population;
D O I
10.1345/aph.1E259
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To present, compare, and contrast the various approaches to estimating population pharmacokinetic (PPK) models with respect to the mathematical foundation, statistical aspects, software programs for implementation, and underlying assumptions. Data Sources: Information on PPK was retrieved from a MEDLINE search (1977-August 2004) of literature and a bibliographic review of review articles and books. This information is used in conjunction with experience to explain the various methodologic approaches to PPK. Study Selection and Data Extraction: All articles indentified from data sources were evaluated and relevant information was included in this review. Data Synthesis: Over 80 articles dealing with PPK estimation methods and/or their implementation were identified and reviewed. Sixty-four of these were chosen for their direct relevance to the subject of this article. Different estimation methods ranging from the naive averaging and naive pooled approaches through the standard two-stage approach to the nonlinear mixed-effects modeling approaches for estimating PPK are reviewed with their advantages and limitations. Conclusions: PPK estimation methods that rely on the characterizing of mixed (fixed and random) effects are known to produce PPK parameter estimates that are less biased than those obtained using the naive and standard two-stage approaches. The NONMEM software is the most widely used software for the characterization of PPK.
引用
收藏
页码:1907 / 1915
页数:9
相关论文
共 64 条
[31]   INTER- + INTRASUBJECT VARIATIONS IN DRUG ABSORPTION KINETICS [J].
LEVY, G ;
HOLLISTER, LE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1964, 53 (12) :1446-&
[32]   NONLINEAR MIXED EFFECTS MODELS FOR REPEATED MEASURES DATA [J].
LINDSTROM, MJ ;
BATES, DM .
BIOMETRICS, 1990, 46 (03) :673-687
[33]  
MALLET A, 1986, BIOMETRIKA, V73, P645
[34]  
MALLET A, 1988, J PHARMACOKINET BIOP, V16, P529
[35]  
MALLET A, 1988, BIOMED MEAS INFOR CO, V2, P673
[36]   PROBLEMS AND PITFALLS IN ESTIMATING AVERAGE PHARMACOKINETIC PARAMETERS [J].
MARTIN, E ;
MOLL, W ;
SCHMID, P ;
DETTLI, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (05) :595-602
[37]   CLINICAL PHARMACOKINETICS OF ZIDOVUDINE - INTER AND INTRAINDIVIDUAL VARIABILITY AND RELATIONSHIP TO LONG-TERM EFFICACY AND TOXICITY [J].
MENTRE, F ;
ESCOLANO, S ;
DIQUET, B ;
GOLMARD, JL ;
MALLET, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (05) :397-407
[38]  
Mentre F, 1995, J Biopharm Stat, V5, P141, DOI 10.1080/10543409508835104
[39]  
MENTRE F, 1992, POPULATION APPROACH, P75
[40]   POPULATION PHARMACOKINETIC ANALYSIS OF DIDANOSINE (2',3'-DIDEOXYINOSINE) PLASMA-CONCENTRATIONS OBTAINED IN PHASE-I CLINICAL-TRIALS IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX [J].
PAI, SM ;
SHUKLA, UA ;
GRASELA, TH ;
KNUPP, CA ;
DOLIN, R ;
VALENTINE, FT ;
MCLAREN, C ;
LIEBMAN, HA ;
MARTIN, RR ;
PITTMAN, KA ;
BARBHAIYA, RH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (03) :242-247